Melatonin and Sleep Quality in Children with ADHD — What a Randomized Trial Showed

Difficulty falling asleep is one of the most common, yet least talked about, problems accompanying ADHD in children. The bedtime routine that takes many families a dozen or so minutes can, for a child with ADHD and chronic sleep-onset insomnia, stretch to an hour or longer — with endless tossing and turning, getting up, requests for one more bedtime story, and mounting frustration on both sides.

The situation is further complicated by the fact that stimulant medications commonly used to treat ADHD, while effective at easing the disorder's core daytime symptoms, can simultaneously worsen evening sleep-onset problems — a known, well-documented side effect of this drug class. As a result, some children with ADHD face a double burden: the difficulties characteristic of the disorder itself, plus an additional, medication-related decline in sleep quality.

Melatonin, a hormone that naturally regulates the body's circadian rhythm, has for years been widely used by parents and recommended by doctors as a way to help children with ADHD fall asleep. A randomized trial from 2007, conducted specifically in this population, allows us to assess how solidly this common practice is actually grounded in data, versus how much it rests mainly on anecdotal experience.

Melatonin is a hormone secreted by the pineal gland in response to falling darkness, signaling to the body that bedtime is approaching and helping synchronize the internal biological clock with the day-night cycle. In some children with ADHD and chronic sleep-onset difficulties, a delay is observed in the body's natural release of melatonin — a phenomenon called delayed dim light melatonin onset (DLMO) — meaning the "time to sleep" signal reaches the body later than it should.

Administering exogenous melatonin at the right time in the evening is meant to speed up this natural signal, thereby making it easier to fall asleep at a reasonable hour. This is a different mechanism from classic sleep medications — melatonin doesn't "sedate" directly through a calming effect, but rather corrects a shifted circadian rhythm, which theoretically makes it especially suited to children whose underlying problem lies in a delayed biological clock rather than general overstimulation.

The magnitude of the improvement in sleep measures in this trial is clear and consistent across several independent measures at once — sleep onset time, the biological DLMO marker, and total sleep time. The fact that all three measures improved in the same direction, with highly statistically significant differences from placebo (p<0.0001 for two of them), significantly strengthens confidence that the effect is real rather than a chance finding.

At first glance, one might expect that if a child sleeps longer and falls asleep faster, this should translate into improved concentration, mood, and daytime behavior — after all, chronic sleep deprivation itself impairs cognitive functioning in any child, regardless of ADHD. The Van der Heijden et al. trial, however, didn't confirm such a relationship within this particular, four-week observation window.

Possible explanations include too short an observation period for the effects of better sleep to translate into measurable behavioral change, independence between the mechanisms underlying sleep-onset difficulties and those responsible for ADHD's core symptoms (attention deficits, hyperactivity), and the fact that improved sleep in a child doesn't necessarily immediately translate into improvement perceived and reported by parents on behavioral questionnaires. Regardless of the exact explanation, this finding is an important warning against overly high expectations for melatonin as an intervention for ADHD.

This distinction matters practically for parents who might expect that improved sleep will "automatically" also improve their child's daytime behavior. According to the available data, this additional effect isn't guaranteed — melatonin is worth considering primarily as a way to address the specific problem of sleep-onset difficulty, not as a complement to treating ADHD's core symptoms.

We discuss melatonin itself more broadly — its mechanism of action, forms, and general dosing principles — in our entry on melatonin, where we also cover its use outside the ADHD context, for example for jet lag or shift work in adults.

Melatonin is one of the few interventions for sleep-onset difficulties in children with ADHD that has been evaluated in a solidly designed randomized trial specifically in this population — and within this narrow scope, the results are encouraging. It's important, however, not to extend this enthusiasm to the full picture of ADHD: this is a tool for a specific sleep problem, not universal support for a child with this disorder.